| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT03339921 Details | 2024-03-05 Interventional | 2/3 | 3 | Botulinum Toxin… Chronic Exertio… Compartment Syn… Syndrome | This study is being closed because it is unworkable. This study was terminated because it is unworkable. | |||
| NCT03151707 Details | 2024-03-05 Interventional | 4 | 11 | Niacin Niacinamide Nicotinic Acids Healthy | Lack of funding and appropriate staff Early termination leading to small numbers of subjects analyzed | |||
| NCT02261883 Details | 2024-03-05 Interventional | 2 | 42 | Treprostinil Hypertension Hypertension, P… Persistent Feta… Persistent Pulm… | Sponsor Decision - | |||
| NCT02013167 2013-000536-10 Details | 2024-03-05 Interventional | 3 | 405 | Blinatumomab Leukemia Leukemia, Lymph… Precursor Cell … Relapsed/Refrac… | - - | |||
| NCT05617313 Details | 2024-03-04 Interventional | 2 | - | Pembrolizumab Carcinoma, Non-… Lung Neoplasms Metastatic NSCL… Non Small Cell … Recurrent Non S… | Interim Analysis - | |||
| NCT05461794 Details | 2024-03-04 Interventional | 2 | 96 | Docetaxel Irinotecan Tislelizumab Carcinoma Carcinoma, Squa… Esophageal Squa… | Due to modification of company strategy. - | |||
| NCT04314843 2019-004568-23 Details | 2024-03-04 Interventional | 1 | 6 | Axicabtagene ci… Cyclophosphamid… Fludarabine Lenzilumab Lymphoma Lymphoma, B-Cel… Relapsed/Refrac… | Development program terminated and the decision was not due to any safety concerns. - | |||
| NCT04152863 2019-002034-36 Details | 2024-03-04 Interventional | 2 | 85 | Pembrolizumab Melanoma Advanced/Metast… | Business Reasons - | |||
| NCT03863288 Details | 2024-03-04 Interventional | 1/2 | 60 | Oxytocin Irritable Mood | Per DSMB's recommendation - | |||
| NCT03319537 Details | 2024-03-04 Interventional | 1/2 | 9 | Pemetrexed Pevonedistat Mesothelioma Mesothelioma, M… | Sponsor terminated study agreement - | |||
| NCT02735343 Details | 2024-03-04 Interventional | 3 | 5 | Ketamine Prochlorperazin… Emergencies Headache | study goals met This study was terminated early due to the study becoming unnecessary due to findings in another trial. | |||
| NCT01156922 Details | 2024-03-04 Interventional | 2 | [1 Refs] | 8 | Rituximab Encephalomyelit… Fatigue Fatigue Syndrom… Myalgia Syndrome Chronic Fatigue… Myalgic Encepha… | Difficulties in logistics handling the very severe patients (travel, hospital stay, follow-up) - | ||
| NCT00019695 NCT00001802 Details | 2024-03-04 Interventional | 2 | - | Alendronate Ketoconazole Adenocarcinoma Neoplasm Metast… Prostatic Neopl… Adenocarcinoma … Bone Metastases Recurrent Prost… Stage IV Prosta… | - - | |||
| NCT00003552 NCT00001739 Details | 2024-03-04 Interventional | 1/2 | - | Antilymphocyte … Cyclophosphamid… Fludarabine Melanoma Recurrent Melan… Stage IV Melano… | - - | |||
| NCT05374603 Details | 2024-03-01 Interventional | 2 | - | Durvalumab Lung Cancer | The sponsor needs to comprehensively evaluate the benefit and risk of the study. - | |||
| NCT05124691 Details | 2024-03-01 Interventional | 2/3 | 992 | Albendazole Ivermectin Helminthiasis Helminthes; Inf… | Primary Endpoint met - | |||
| NCT04920383 Details | 2024-03-01 Interventional | 1 | 29 | Pembrolizumab Neoplasms Advanced Solid … Lymphoma | Sponsor decision - | |||
| NCT04128956 2019-001723-12 Details | 2024-03-01 Interventional | 2 | 172 | Aspirin Thrombosis Venous Thrombos… Stent Stenosis Venous Thrombos… | Recommendation by DSMB - | |||
| NCT03806751 Details | 2024-03-01 Interventional | 1 | 0 | Acetazolamide Validation of a… | The investigator decided not to pursue the study. - | |||
| NCT03781986 Details | 2024-03-01 Interventional | 1/2 | - | Carboplatin Salivary Gland … Malignant Saliv… Salivary Gland … | enrollment has been placed on hold, pending evaluability assessment - |